+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Basic data supporting the use of the l-lysine salt of bendazac in cataract

Basic data supporting the use of the l-lysine salt of bendazac in cataract

International Journal of Tissue Reactions 5(2): 217-225

Bendazac, as such or in the form of its l-lysine salt, has a protective effect against lens protein denaturation both in vitro and in vivo. In vitro this effect has been documented on the lens proteins of rats, rabbits and pigs by using nephelometry, electrophoresis and electron microscopy. In vivo the protective effect has been observed after treatments ranging in duration from 3 to 14 days depending on the dosage used; the minimal effective dose produced a serum level of 35 micrograms/ml of bendazac. The penetration of the drug into the lens has been shown by both radioassay and HPLC; the lens concentration of bendazac increases with the duration of treatment. The mechanism of the protective action of bendazac against lens protein denaturation is discussed together with the implications of such protective action in the treatment of cataract.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 042364950

Download citation: RISBibTeXText

PMID: 6618787

Related references

Critical evaluation of bendazac lysine salt in the treatment of cataract. Bollettino di Oculistica 63(11-12): 1271-1282, 1984

Treatment of early cortical cataract experience with bendazac lysine salt. Prensa Medica Argentina 72(11): 380-383, 1985

Effects of bendazac L-lysine salt on X-ray-induced cataract in the rabbit lens. Experimental Eye Research 42(2): 167-175, 1986

Bendazac Lysine in Selected Types of Human Senile Cataract. Ophthalmic Research 21(3): 141-154, 1989

Hepatotoxicity due to lysine salt of bendazac. Scandinavian Journal Of Gastroenterology. 31(2): 206-208, 1996

Clinical evaluation of topical bendazac lysine in treatment of senile cataract. Bollettino di Oculistica 67(1): 25-30, 1988

Senile and presenile cataract therapy with bendazac lysine a clinical evaluation. Bollettino di Oculistica 65(4): 671-684, 1986

Clinical trial of bendazac lysine eye drops in the medical treatment of cataract. Bollettino di Oculistica 68(5): 823-834, 1989

Plasma levels and metabolism of bendazac lysine salt in man. Bollettino Chimico Farmaceutico 125(8): 298-302, 1986

Contrast sensitivity in patients with cataract submitted to chronic treatment with bendazac lysine eye drops. Annali di Ottalmologia e Clinica Oculistica 114(10): 1001-1020, 1988

Medical treatment of senile cataract: clinical investigation of bendazac-lysine using objective and subjective methods. Graefe's Archive for Clinical and Experimental Ophthalmology 228(2): 105-111, 1990

Oral absorption of bendazac lysine salt in man after repeated administrations. Pharmacological Research Communications 15(5): 461-472, 1983

Inhibition of rat lens aldose reductase by bendazac-L-lysine salt. Enzyme 42(4): 235-237, 1989

A comparative study of the oral absorption in man of bendazac and its lysine salt. Bollettino Chimico Farmaceutico 121(2): 87-90, 1982

Can bendazac lysine salt be effective on the blood retinal barrier in diabetics. Annali di Ottalmologia e Clinica Oculistica 112(9): 803-806, 1987